Hyperthyroidism is a common disease mainly manifested by hyperexcitability of multiple systems and hypermetabolism. Currently, antithyroid drugs (ATDs), radioiodine therapy (RIT), and surgery are mainly used in the clinical treatment for primary hyperthyroidism. We reported a case of a 28-year-old female who received a novel treatment for primary hyperthyroidism. This patient had poor control of thyroid function while taking ATD, and her oral Methimazole (MMI) dose varied repeatedly between 20 mg qd and 15 mg qd, failing to maintain a stable status. To minimize the possible complication and to achieve drug reduction or withdrawal, she refused RIT and surgery and showed up in our department. The patient, diagnosed with Graves’ disease (GD) and met the surgical indication after systematic clinical evaluation, was subject to ultrasound-guided percutaneous microwave ablation (MWA) of the partial thyroid gland with continuous oral administration of 20 mg qd MMI. The post-ablation condition was stable and the patient was discharged 2 days after the operation. Thyroid ultrasound and serum thyroid function test were examined regularly after ablation and the MMI dosage was gradually reduced according to the results of the biochemical examination. Five weeks after the operation, the patient completely discontinued the medication. Ultrasound-guided percutaneous microwave ablation is minimally invasive, safe, and effective, and has potential to be an alternative treatment besides the 3 classical treatments of hyperthyroidism.
SingerPA, CooperDS, LevyEG, LadensonPW, BravermanLE, DanielsG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995;273(10):808–12.
2.
Association ESoCMGuidelines for the diagnosis and treatment of thyroid diseases in China——hyperthyroidism. Chin J Intern Med. 2007;46(10):876–82.
3.
BahnRS, BurchHB, CooperDS, GarberJR, GreenleeMC, KleinI, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456–520.
4.
RossDS, BurchHB, CooperDS, GreenleeMC, LaurbergP, MaiaAL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421.
5.
CheY, JinS, ShiC, WangL, ZhangX, LiY, et al. Treatment of Benign Thyroid Nodules: Comparison of Surgery with Radiofrequency Ablation. AJNR Am J Neuroradiol. 2015;36(7):1321–5.
6.
HaEJ, BaekJH, KimKW, PyoJ, LeeJH, BaekSH, et al. Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network meta-analysis. J Clin Endocrinol Metab. 2015;100(5):1903–11.
7.
Ji HongM, BaekJH, ChoiYJ, LeeJH, LimHK, ShongYK, et al. Radiofrequency ablation is a thyroid function-preserving treatment for patients with bilateral benign thyroid nodules. J Vasc Interv Radiol. 2015;26(1):55–61.
8.
ZhangC, YinJ, HuC, YeQ, WangP, HuangP. Comparison of ultrasound guided percutaneous radiofrequency ablation and open thyroidectomy in the treatment of low-risk papillary thyroid microcarcinoma: A propensity score matching study. Clin Hemorheol Microcirc. 2021.
9.
RyuT, TakamiY, WadaY, HaraT, SasakiS, SaitsuH. Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma< /=5 cm: A propensity score-matched analysis. Surgery. 2019;166(3):254–62.
10.
RennertJ, WiesingerI, BeyerLP, SchichoA, StroszczynskiC, WiggermannP, et al. Color coded perfusion analysis and microcirculation imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following thermal ablative techniques of primary and secondary liver malignancies. Clin Hemorheol Microcirc. 2019;73(1):73–83.
11.
ChuKF, DupuyDE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.
12.
FacciorussoA, Di MasoM, MuscatielloN. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 2016;32(3):339–44.
13.
SmithTJ, HegedusL. Graves’ Disease. N Engl J Med. 2016;375(16):1552–65.
14.
KahalyGJ, BartalenaL, HegedusL, LeenhardtL, PoppeK, PearceSH. European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.
15.
BartalenaL. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–34.
16.
BiondiB, KahalyGJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6(8):431–43.
17.
KahalyGJ, DillmannWH. Thyroid hormone action in the heart. Endocr Rev. 2005;26(5):704–28.
18.
TraiskF, TallstedtL, Abraham-NordlingM, AnderssonT, BergG, CalissendorffJ, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94(10):3700–7.
19.
BahnRS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38.
20.
EcksteinAK, PlichtM, LaxH, NeuhauserM, MannK, LederbogenS, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91(9):3464–70.
21.
BartalenaL, ChiovatoL, VittiP. Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest. 2016;39(10):1105–14.
22.
SpencerCA, LoPrestiJS, PatelA, GuttlerRB, EigenA, ShenD, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990;70(2):453–60.
23.
BartalenaL, BurchHB, BurmanKD, KahalyGJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016;84(1):115–20.
24.
de los SantosET, StarichGH, MazzaferriEL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149(3):526–32.
25.
HegedusL. Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001;30(2):339–60, viii-ix.
26.
VittiP, RagoT, MancusiF, PalliniS, TonaccheraM, SantiniF, et al. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves’ disease. Acta Endocrinol (Copenh). 1992;126(2):128–31.
27.
KleinI, BeckerDV, LeveyGS. Treatment of hyperthyroid disease. Ann Intern Med. 1994;121(4):281–8.
28.
SundareshV, BritoJP, WangZ, ProkopLJ, StanMN, MuradMH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671–7.
29.
ElbersL, MouritsM, WiersingaW. Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid. 2011;21(3):279–83.
30.
AziziF, AtaieL, HedayatiM, MehrabiY, SheikholeslamiF. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005;152(5):695–701.
31.
BritoJP, Castaneda-GuarderasA, GionfriddoMR, OspinaNS, MarakaS, DeanDS, et al. Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves’ Disease. Thyroid. 2015;25(11):1191–8.
32.
Abraham-NordlingM, TorringO, HambergerB, LundellG, TallstedtL, CalissendorffJ, et al. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005;15(11):1279–86.
33.
BartalenaL, MarcocciC, BogazziF, PanicucciM, LepriA, PincheraA. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321(20):1349–52.
34.
TulandiT. Microwaves: from the kitchen to the operating theatre. CMAJ. 1999;161(9):1132.
35.
HappelC, KorkusuzH, KochDA, GrunwaldF, KranertWT. Combination of ultrasound guided percutaneous microwave ablation and radioiodine therapy in benign thyroid diseases. A suitable method to reduce the 131I activity and hospitalization time?Nuklearmedizin. 2015;54(3):118–24.
36.
LubnerMG, BraceCL, HinshawJL, LeeFTJr.Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21(8 Suppl):192–203.
37.
WrightAS, LeeFTJr, MahviDM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10(3):275–83.
38.
SidhuPS, CantisaniV, DietrichCF, GiljaOH, SaftoiuA, BartelsE, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018;39(2):e2–e44.
39.
ZhaoH, LiuX, LeiB, ChengP, LiJ, WuY, et al. Diagnostic performance of thyroid imaging reporting and data system (TI-RADS) alone and in combination with contrast-enhanced ultrasonography for the characterization of thyroid nodules. Clin Hemorheol Microcirc. 2019;72(1):95–106.
